Physical Activity in Polycythemia Vera: Benefits, Risks and Evidence-Based Exercise Recommendations - A Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.56.72507Keywords
polycythemia vera, physical activity, myeloproliferative neoplasms, quality of lifeAbstract
Background. Polycythemia vera (PV) is a type of Philadelphia-negative myeloproliferative neoplasm (MPN) associated with a good prognosis but possible serious complications. Although medications lower hematocrit and reduce thrombosis risk, patients and clinicians underuse non-drug approaches such as physical activity (PA), despite growing evidence for their help while dealing with the disease’s symptoms and complications.
Aim: This study aims to identify and evaluate the safest and most effective types of physical activity specifically recommended for patients diagnosed with PV.
Methods: A brief review of studies examining physical activity in patients with PV or other MPNs was conducted using PubMed, ScienceDirect, American Society of Hematology publications and Google Scholar.
Results: Regular PA of moderate intensity, such as walking, swimming, or cycling, for 150–300 minutes per week is safe in well-controlled PV (hematocrit < 45%). This level of activity reduces the most common PV complication - fatigue - by 30–50%, but also soothes aquagenic pruritus, especially during water-based exercise, helps with concentration problems, and decreases bone or muscle pain.
Discussion and conclusions: Tailored physical activity for patients with polycythemia vera shows promising results in reducing common symptoms. However, further research is needed to develop optimal activity recommendations for all patient groups.
References
1. Felser, S., Rogahn, J., Hollenbach, L., Gruen, J., le Coutre, P., Al-Ali, H-K., Schulze, S., Muegge, L-O., Kraze-Kliebhahn, V., Junghanss, C. Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97). 2023 Sep;12(17):18235-18245. https://doi.org/10.1002/cam4.6413
2. Doğan, E., Karadağ, F., Aydin, D., Demirel, N., Sağlam, S., Davulcu, E., Erkek, E., Eren, R., Soyer, N., Sahin, F., Saydam, G. The assessment of health-related quality of life in patients with polycythemia vera. 2024 Jul 26;103(30):e38814. https://doi.org/10.1097/md.0000000000038814
3. Eckert, R., Huberty, J., Gowin, K., Mesa, R., Marks, L. Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research. 2017 Dec;16(4):439-450. https://doi.org/10.1177/1534735416661417
4. Geyer, H., Scherber, R., Kosiorek, R., Dueck, A., Kiladjian, J-J., Xiao, Z., Slot, S., Zweegman, S., Sackmann, F., Fuentes, A., Hernández-Maraver, D., Döhner, K., Harrison, K., Radia, D., Muxi, P., Besses, C., Cervantes, F., Johansson, P., Andreasson, B., Rambaldi, A., et al. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease 2016 Jan 10;34(2):151-9. https://doi.org/10.1200/jco.2015.62.9337
5. Stein, B., Moliterno, A., Tiu, R. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. 2014 Dec;93(12):1965-76. https://doi.org/10.1007/s00277-014-2205-y
6. Spivak, J. Polycythemia vera: myths, mechanisms, and management. (2002) 100 (13): 4272–4290. https://doi.org/10.1182/blood-2001-12-0349
7. Finazzi, G., Barbui, T. How I treat patients with polycythemia vera. (2007) 109 (12): 5104–5111. https://doi.org/10.1182/blood-2006-12-038968
8. Dagenais-Bellefeuille, S., Bilodeau, K., Poullet, A., Sirhan, S., Delage, R., Cournoyer, G., Chamakhi, I., Talbot, D., Mollica, L., Marceau, D., Ethier, V., Desjardins, P., Olney, H. J., Harnois, M., Busque, L., Szuber, N. Understanding the Lived Experience of Fatigue in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Mixed Methods Study. (2024) 144 (Supplement 1):408. https://doi.org/10.1182/blood-2024-206225
9. Mesa, R. A., Kosiorek, H. E., Mascarenhas, J., Prchal, J. T., Rambaldi, A., Berenzon, D., Yacoub, A., Harrison, C. N., McMullin, M. F., Vannucchi, A. M., Ewing, J., O'Connell, C. L., Kiladjian, J.-J., Mead, A. J., Winton, E. F., Leibowitz, D. S., De Stefano, V., Arcasoy, M. O., Kessler, C. M., Catchatourian, R. Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. (2018) 132 (Supplement 1): 3032. https://doi.org/10.1182/blood-2018-99-111929
10. Tolstrup Larsen, R., Tang, L. H., Brochmann, N., Flachs, E. M., Christensen, A. I., Hasselbalch, H. C., Zwisler, A.-D. Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms. 2018 Jun;100(6):550-559. https://doi.org/10.1111/ejh.13048
11. McTiernan, A., Friedenreich, C. M., Katzmarzyk, P. T., Powell, K. E., Macko, R., Buchner, D., Pescatello, L. S., Bloodgood, B., Tennant, B., Vaux-Bjerke, A., George, S. M., Troiano, R. P., Piercy, K. L. Physical Activity in Cancer Prevention and Survival: A Systematic Review. 2019 Jun;51(6):1252-1261. https://doi.org/10.1249/mss.0000000000001937
12. Sweegers, M. G., Altenburg, T. M., Chinapaw, M. J., Kalter, J., Verdonck-de Leeuw, I. M., Courneya, K. S., Newton, R. U., Aaronson, N. K., Jacobsen, P. B., Brug, J., Buffart, L. M. Which exercise prescriptions improve quality of life and physical function in patients with cancer during and following treatment? A systematic review and meta-analysis of randomised controlled trials. 2018 Apr;52(8):505-513. https://doi.org/10.1136/bjsports-2017-097891
13. Torregrosa, C., Chorin, F., Molina Beltran, E. E., Neuzillet, C., Cardot-Ruffino, V. Physical Activity as the Best Supportive Care in Cancer: The Clinician's and the Researcher's Perspectives. 2022 Nov 2;14(21):5402. https://doi.org/10.3390/cancers14215402
14. Yang, Y.-P., Pan, S.-J., Qiu, S.-L., Tung, T.-H. Effects of physical exercise on the quality-of-life of patients with haematological malignancies and thrombocytopenia: A systematic review and meta-analysis. 2022 Apr 6;10(10):3143-3155. https://doi.org/10.12998/wjcc.v10.i10.3143
15. Tefferi, A., Barbui, T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. 2023 Sep;98(9):1465-1487. https://doi.org/10.1002/ajh.27002
16. Brochmann, N., Flachs, E. M., Christensen, A. I., Bak, M., Andersen, C. L., Juel, K., Hasselbalch, H. C., Zwisler, A.-D., Rottmann, N. Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. 2018 Dec 18:11:23-33. https://doi.org/10.2147/clep.s162688
17. Mesa, R. A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., Tan, A. D., Atherton, P. J., Sloan, J. A., Tefferi, A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. 2007 Jan 1;109(1):68-76. https://doi.org/10.1002/cncr.22365
18. Surapaneni, P., Scherber, R. M. Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions. 2019 Jun;14(3):164-170. https://doi.org/10.1007/s11899-019-00516-w
19. Harrison, C. N., Koschmieder, S., Foltz, L., Guglielmelli, P., Flindt, T., Koehler, M., Mathias, J., Komatsu, N., Boothroyd, R. N., Spierer, A., Perez Ronco, J., Taylor-Stokes, G., Waller, J., Mesa, R. A. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. 2017 Oct;96(10):1653-1665. https://doi.org/10.1007/s00277-017-3082-y
20. Titmarsh, G. J., Duncombe, A. S., McMullin, M. F., O'Rorke, M., Mesa, R., De Vocht, F., Horan, S., Fritschi, L., Clarke, M., Anderson, L. A. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. 2014 Jun;89(6):581-7. https://doi.org/10.1002/ajh.23690
21. Borsati, A., Murri, A., Natalucci, V., Cerulli, C., Barbieri, E., Lucertini, F., Lanza, M., Parisi, A., Galvani, C., Buono, P., Mancini, A., Fischetti, F., Poli, L., Di Blasio, A., Iannaccone, A., Avancini, A., Mauri, C., Ferri Marini, C., Grazioli, E. The Effect of Exercise-Based Interventions on Health-Related Quality of Life of Patients with Hematological Malignancies: A Systematic Review and Meta-Analysis. 2025 Feb 21;13(5):467. https://doi.org/10.3390/healthcare13050467
22. Patel, A. B., Masarova, L., Mesa, R. A., Hobbs, G., Pemmaraju, N. Polycythemia vera: past, present and future. 2024 Nov;65(11):1552-1564. https://doi.org/10.1080/10428194.2024.2361836
23. Reiter, A., Harrison, C. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. 2016 Oct;11(5):356-67. https://doi.org/10.1007/s11899-016-0311-8
24. Tefferi, A., Vannucchi, A. M., Barbui, T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. 2021 Dec;35(12):3339-3351. https://doi.org/10.1038/s41375-021-01401-3
25. Tefferi, A., Barbui, T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. 2020 Dec;95(12):1599-1613. https://doi.org/10.1002/ajh.26008
26. Mønsted Pedersen, K., Zangger, G., Brochmann, N., Mygind Grønfeldt, B., Zwisler, A.-D., Hasselbalch, H. C., Tang, L. H. The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms-An explorative study. 2018 Sep;27(5):e12865. https://doi.org/10.1111/ecc.12865
27. Knips, L., Bergenthal, N., Streckmann, F., Monsef, I., Elter, T., Skoetz, N. Aerobic physical exercise for adult patients with haematological malignancies. 2019 Jan 31;1(1):CD009075. https://doi.org/10.1002/14651858.cd009075.pub3
28. Horneber, M., Fischer, I., Dimeo, F., Rüffer, J. U., Weis, J. Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. 2012 Mar;109(9):161-71. https://doi.org/10.3238/arztebl.2012.0161
29. Felser, S., Rogahn, J., le Coutre, P., Al-Ali, H. K., Schulze, S., Muegge, L.-O., Gruen, J., Geissler, J., Kraze-Kliebhahn, V., Junghanss, C. Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97). 2023 Jan 4:12:1056786. https://doi.org/10.3389/fonc.2022.1056786
30. Singh, S., Peshin, S., Larsen, A., Gowin, K. Optimizing Care: Integrative Oncology in Myeloproliferative Neoplasm. 2024 Oct;26(10):1135-1145. https://doi.org/10.1007/s11912-024-01568-9
31. Mesa, R., Miller, C. B., Thyne, M., Mangan, J., Goldberger, S., Fazal, S., Ma, X., Wilson, W., Paranagama, D. C., Dubinski, D. G., Boyle, J., Mascarenhas, J. O. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. 2016 Feb 27:16:167. https://doi.org/10.1186/s12885-016-2208-2
32. Mesa, R. A., Wadleigh, M., Niblack, J., Gilliland, D. G., Verstovsek, S., Camoriano, J., Solberg, L., Barnes, S., Sloan, J., Atherton, P., Tan, A., Tefferi, A. Fatigue, the Un-Addressed Curse of Myeloproliferative Diseases (MPD): Results of an International Internet Based QOL Survey of 830 MPD Patients. (2005)106(11):2577. https://doi.org/10.1182/blood.V106.11.2577.2577
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Kacper Ściebura, Natalia Mordal, Damian Zienkiewicz, Gabriela Makulec, Karolina Domosud, Weronika Walendziak, Wiktoria Wiśniewska, Magdalena Ostaszewska, Milena Majchrzyk, Anna Malczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 28
Number of citations: 0
